AMARIN CORP PLC\UK Proceeds from Debt, Net of Issuance Costs
AMARIN CORP PLC\UK (AMRN) reported Proceeds from Debt, Net of Issuance Costs of $99.73 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-03-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2015-03-03
- AMARIN CORP PLC\UK proceeds from debt, net of issuance costs for fiscal 2012 was $99.73M.
| Period end | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|
| 2012-12-31 | $99.73M 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |